Organisation paid for research Program year 2025 Source: CMS Open Payments

Jem Research Institute

Neither a doctor nor a teaching hospital

Research payments

$10,784,394

170 payments

Through program year 2025, Jem Research Institute is reported as receiving $10,784,394 in research payments, across 170 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $823,907 13
2024 Research $592,953 19
2023 Research $2,287,345 13
2022 Research $2,488,111 85
2021 Research $2,220,621 12
2020 Research $1,724,578 12
2019 Research $646,878 16

Breakdown

Who paid Research payments · program years 2019–2025
  1. Biogen, Inc. $5,133,161 20 payments
  2. AstraZeneca Pharmaceuticals LP $1,556,254 2 payments
  3. Novartis Pharmaceuticals Corporation $1,463,171 13 payments
  4. Genentech, Inc. $1,077,499 79 payments
  5. Merck Sharp & Dohme Corporation $840,571 14 payments
  6. E.R. Squibb & Sons, L.L.C. $683,174 8 payments
  7. GlaxoSmithKline, LLC. $19,543 10 payments
  8. Amgen Inc. $5,267 2 payments
  9. Pfizer Inc. $4,703 11 payments
  10. AbbVie, Inc. $600 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 3b/4 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Verify the Clinical Benefit of Aducanumab (BIIB037) in Participants With Alzheimer's Disease $2,175,778 5 payments
  2. A Phase III Randomized Double-blind Placebo-controlled Multicenter Study in Adults to Determine the Safety Efficacy and Immunogenicity of AZD1222 a Non-replicating ChAdOx1 Vector Vaccine for the Prevention of COVID-19 $1,556,254 2 payments
  3. An Open Label Single Arm Multi Center Extension Study Evaluating Long Term Safety Tolerability and Effectiveness of Ofatumumab in Subjects With Relapsing Multiple Sclerosis $1,390,909 9 payments
  4. A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205 $1,310,970 1 payment
  5. Phase 2 Study of BIIB092 in Participants With Early Alzheimer's Disease $613,377 2 payments
  6. Phase 3b Open-Label, Multicenter, Safety Study of BIIB037 (aducanumab) in Subjects with Alzheimer's disease Who Had Previously Participated in the Aducanumab Studies221AD103, 221AD301, 221AD302 and 221AD205 $492,514 1 payment
  7. A Randomized, Double-blind, Placebo-controlled, Global Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986446, an Anti-MTBR Tau Monoclonal Antibody, in Participants with Early Alzheimers Disease (TargetTau-1) $492,477 3 payments
  8. Phase 3b Open-Label, Multicenter, Safety Study of BIIB037 (aducanumab) in Subjects with Alzheimers disease Who Had Previously Participated in the Aducanumab Studies221AD103, 221AD301, 221AD302 and 221AD205 $475,194 3 payments
  9. A Phase 2,3, Randomized, Placebo-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of MK-4482 in Non-Hospitalized Adults with COVID-19. $428,902 4 payments
  10. A Phase 3, Randomized, Double-blind, Active Comparator-controlled Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine na Adults $407,774 6 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record